Understanding how loss of NF1 contributes to breast cancer in a rat model
Loss of NF1 drives hormone dependent mammary carcinogenesis in a rat model with intact immune system
This study is looking at how changes in the NF1 gene might contribute to breast cancer, especially in tumors that depend on hormones, using rat models to better understand how these changes affect tumor growth and treatment responses, with the goal of finding better ways to help patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Alabama at Birmingham NIH-funded |
| Lab location | 1 site (Birmingham, United States) |
| Project ID | NIH-10873802 on NIH RePORTER |
What this research studies
This research investigates the role of the NF1 gene in breast cancer development, particularly focusing on how its loss can lead to hormone-dependent tumors. Using specially designed rat models that mimic human breast cancer, the study examines how different NF1 mutations affect tumor growth and response to treatments. By analyzing these models, researchers aim to uncover the mechanisms behind NF1's influence on cancer progression and treatment resistance, which could lead to improved therapeutic strategies for patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with breast cancer, particularly those with known NF1 mutations or those who are estrogen receptor positive.
Not a fit: Patients without breast cancer or those whose tumors do not involve NF1 mutations may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to better understanding and treatment options for breast cancer patients with specific NF1 mutations.
How similar studies have performed: Previous research has shown that targeting genetic mutations like NF1 can lead to significant advancements in understanding cancer biology, indicating potential for success in this approach.
Where this research is happening
Birmingham, United States
- University of Alabama at Birmingham — Birmingham, United States (Active)
Researchers
- Principal investigator: Wallis-Schultz, Deeann — University of Alabama at Birmingham
- Study coordinator: Wallis-Schultz, Deeann
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.